Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.66 |
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.48 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.48 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21887079 | 0.94 | GPR119 (0.58) | GPR119 | |
| SCHEMBL21886886 | 0.94 | GPR119 (0.58) | GPR119 | |
| SCHEMBL21886888 | 0.94 | GPR119 (0.58) | GPR119 | |
| SCHEMBL14302003 | 0.89 | GPR119 (0.52) | GPR119DPP4DPP8DPP9IRAK4 | |
| SCHEMBL31753279 | 0.84 | GPR119 (0.51) | GPR119 | |
| SCHEMBL31748202 | 0.84 | GPR119 (0.67) | GPR119 | |
| SCHEMBL13993542 | 0.84 | GPR119 (0.67) | GPR119 | |
| SCHEMBL27226467 | 0.83 | GPR119 (0.61) | GPR119ALK | |
| SCHEMBL1575819 | 0.83 | GPR119 (0.57) | GPR119 | |
| SCHEMBL22825487 | 0.83 | GPR119 (0.66) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025262297-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| EP-4594318-A1 | AKT1 MODULATORS | Alterome Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250092040-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-03-20 | — | — | US | disclosed |
| US-20240239797-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-11999730-B1 | AKT1 modulators | ALTEROME THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240174667-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2024073371-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| EP-4238974-A1 | HIGH-ACTIVITY WNT PATHWAY INHIBITOR COMPOUND | Adlai Nortye Biopharma Co., Ltd. (CN) | 2023-09-06 | — | — | EP | disclosed |
| US-20210122763-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN-CILAG S.A. (ES) | 2021-04-29 | — | — | US | disclosed |
| US-20140088124-A1 | IMIDAZOLE DERIVATIVES | INTERVET INC. | 2014-03-27 | — | — | US | disclosed |
| US-7196100-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196100-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-03-27 | — | — | US | disclosed |
| US-20070015807-A1 | Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists | SCHERING CORPORATION | 2007-01-18 | — | — | US | disclosed |
| US-20070010558-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY PATENT DIVISION (US) | 2007-01-11 | — | — | US | disclosed |
| US-20070010558-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY PATENT DIVISION (US) | 2007-01-11 | — | — | US | disclosed |
| US-20070010558-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY PATENT DIVISION (US) | 2007-01-11 | — | — | US | disclosed |
| WO-2007001975-A1 | PIPERIDINE DERIVATIVES USEFUL AS HISTAMINE H3 ANTAGONISTS | SCHERING CORPORATION (US) | 2007-01-04 | — | — | WO | disclosed |
| EP-1697307-A1 | OPIOID RECEPTOR ANTAGONISTS | Eli Lilly & Company (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005061442-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-07-07 | — | — | WO | disclosed |
| US-6313127-B1 | FOR THERAPY OF HYPERCHOLESTEROLEMIA OR ATHEROSCLEROSIS | ZENECA LIMITED (GB) | 2001-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239797-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | GPR119 384/4885DPP4 3051/4885DPP8 2496/4885 |
| US-20210122763-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | GPR119 1166/4885DPP4 846/4885DPP8 917/4885 |
| US-20140088124-A1 | IMIDAZOLE DERIVATIVES | DGAT1, DGAT2, SOAT1 | GPR119 6/4885DPP4 516/4885DPP8 381/4885 |
| US-20250092040-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | GPR119 384/4885DPP4 3051/4885DPP8 2496/4885 |
| US-11999730-B1 | AKT1 modulators | AKT1S1, AKT1, AKT2 | GPR119 384/4885DPP4 3051/4885DPP8 2496/4885 |
| US-20070015807-A1 | Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists | HRH3, HRH4, CHRM2 | GPR119 44/4885DPP4 3225/4885DPP8 3008/4885 |
| US-20070010558-A1 | Opioid receptor antagonists | OPRM1, OPRK1, OPRL1 | GPR119 17/4885DPP4 1387/4885DPP8 1850/4885 |
| US-20240174667-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | GPR119 384/4885DPP4 3051/4885DPP8 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.